Showing results (171-180 of 403) with videos related to

Sort By:
Pageof 41
Journal of the National Cancer Institute|November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified NeuroblastomaEric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
Pediatric Blood & Cancer|November 5, 2011
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signalingE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Pediatric Blood & Cancer|October 28, 2016
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Richard Gorlick, E Anders Kolb, et al.
Pediatric Blood & Cancer|January 29, 2010
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)John M Maris, Christopher L Morton, Richard Gorlick, et al.
Pediatric Blood & Cancer|June 18, 2011
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing ProgramPeter J Houghton, Min H Kang, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|November 28, 2018
The challenge of defining "ultra-high-risk" neuroblastomaDaniel A Morgenstern, Rochelle Bagatell, Susan L Cohn, et al.
Pediatric Blood & Cancer|June 27, 2013
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing programAndrew C Wood, John M Maris, Richard Gorlick, et al.
Pediatric Blood & Cancer|December 18, 2009
Initial testing of topotecan by the pediatric preclinical testing programHernan Carol, Peter J Houghton, Christopher L Morton, et al.
Pediatric Blood & Cancer|March 2, 2011
Initial testing of lenalidomide by the pediatric preclinical testing programC Patrick Reynolds, Min H Kang, Stephen T Keir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Pageof 41